Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 April, 2015 05:27 IST
Glenmark Q3 profit surges 4.75 times
Source: IRIS | 29 Jan, 2013, 04.28PM
Comments  |  Post Comment

Glenmark Pharmaceuticals reported a surge of 4.75 times in consolidated net profit to Rs 2,129.17 million for the quarter ended Dec. 31, 2012 as compared to Rs 448.24 million in the same period last year. During the quarter, the company received out-licensing revenue of Rs. 493.03 million from Forest Laboratories.

Consolidated revenue has increased by 33.96% to Rs 13.81 billion for the quarter ended  Dec. 31, 2012 from Rs 10.31 billion in the year ago period.

Revenue from the generics business was at Rs 5.80 billion, as against Rs 4.36 billion, a growth of 33%.

Glenmark Generics Inc., U.S.A. registered revenue from sale of finished dosage formulations was Rs 4.36 billion for the quarter ended Dec 31, 2012 against revenue of Rs 3.19 billion for the previous corresponding quarter, recording an increase of 36.83%.

''We continue to maintain our high growth trajectory by recording a strong sales growth of over 30 % for the third quarter. The US, India and Russia markets performed exceptionally well and continue to drive growth for the company,'' said Glenn Saldanha, chairman and MD, Glenmark Pharmaceuticals. (Q,N,C,F)*

''The option agreement with Forest Laboratories for the development of novel mPGES-1 inhibitors and the USFDA approval for Glenmark's in-licensed molecule - Crofelemer has come as a big boost and renewed validation for our world-class Drug Discovery apabilities. While the option agreement with Forest Labs marks our seventh outlicensing deal in the innovation R&D space; the USFDA approval for Crofelemer has paved the way for Glenmark becoming the first Indian company to launch an New Chemical Entity (NCE) across multiple geographies,'' he added.

Shares of the company unchanged to settle at Rs 504.05. The total volume of shares traded was 133,269 at the BSE (Tuesday).

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Related Articles
KNR Constructions bag orders worth Rs 9.37 bn - 17-Apr-2015 18:16
Piramal Enterprises to acquire majority stake in Health SuperHiway - 17-Apr-2015 16:35
Reliance Q4 earnings beat estimates; revenue slumps on weak oil price - 17-Apr-2015 16:26
PNB slashes fixed deposit rates by 0.25% - 17-Apr-2015 13:09
TCS: How analysts read Q4 numbers - 17-Apr-2015 11:50
CRISIL assigns fundamental grade 3/5 to Ram Ratna Wires - 17-Apr-2015 11:30
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer